Total Payments
$25,732
2024 Payments
$18,562
Companies
8
Transactions
33
Medicare Patients
569
Medicare Billing
$100,827
Payment Breakdown by Category
Other$11,440 (44.5%)
Research$7,670 (29.8%)
Consulting$4,436 (17.2%)
Travel$1,349 (5.2%)
Food & Beverage$825.76 (3.2%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,655 | 3 | 37.5% |
| Unspecified | $7,670 | 9 | 29.8% |
| Consulting Fee | $4,436 | 3 | 17.2% |
| Honoraria | $1,435 | 2 | 5.6% |
| Travel and Lodging | $1,349 | 5 | 5.2% |
| Food and Beverage | $825.76 | 9 | 3.2% |
| Grant | $350.00 | 1 | 1.4% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$18,062
24 transactions
Research
$7,670
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $24,599 | 23 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $560.71 | 3 | $0 (2024) |
| Athenex Pharmaceutical Division, LLC | $175.00 | 1 | $0 (2020) |
| Stryker Corporation | $120.25 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $107.97 | 2 | $0 (2024) |
| Stemline Therapeutics Inc. | $97.01 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $60.59 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $12.33 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,562 | 23 | PFIZER INC. ($17,688) |
| 2023 | $3,761 | 4 | PFIZER INC. ($3,761) |
| 2022 | $1,260 | 1 | PFIZER INC. ($1,260) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $175.00 | 1 | Athenex Pharmaceutical Division, LLC ($175.00) |
| 2019 | $1,890 | 1 | PFIZER INC. ($1,890) |
| 2018 | $60.59 | 1 | Merck Sharp & Dohme Corporation ($60.59) |
| 2017 | $12.33 | 1 | Novartis Pharmaceuticals Corporation ($12.33) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $138.11 | General |
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $113.75 | General |
| Category: Oncology | ||||||
| 10/28/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,900.00 | General |
| 10/28/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $145.75 | General |
| 10/15/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| 10/01/2024 | PFIZER INC. | IBRANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,155.00 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Stryker Corporation | GAMMA (Device) | Food and Beverage | In-kind items and services | $120.25 | General |
| Category: TRAUMA & EXTREMETIES | ||||||
| 08/24/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $97.01 | General |
| Category: Oncology | ||||||
| 08/22/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: PF06647263 CLINICAL PUBLICATION PROGRAM | ||||||
| 08/02/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 07/24/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $96.05 | General |
| Category: ONC | ||||||
| 06/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $96.96 | General |
| Category: Oncology | ||||||
| 05/16/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 05/07/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 04/23/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 03/08/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $270.57 | General |
| 03/08/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $257.57 | General |
| 03/04/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $145.77 | General |
| 02/20/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $389.40 | General |
| 02/20/2024 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $285.72 | General |
| 02/13/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 02/06/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 02/06/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PALBOCICLIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/23/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 06/05/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $90.71 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 6 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 126 | 206 | $129,145 | $22,916 |
| 2022 | 3 | 131 | 263 | $160,598 | $28,958 |
| 2021 | 6 | 187 | 360 | $174,659 | $37,603 |
| 2020 | 4 | 125 | 154 | $46,525 | $11,349 |
Total Patients
569
Total Services
983
Medicare Billing
$100,827
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 66 | $47,828 | $7,706 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 48 | $35,080 | $5,700 | 16.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 26 | $10,374 | $2,620 | 25.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 37 | $10,286 | $2,442 | 23.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $13,224 | $2,301 | 17.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $12,353 | $2,148 | 17.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 32 | 98 | $39,102 | $8,558 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 38 | 73 | $52,008 | $8,155 | 15.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 35 | 66 | $47,010 | $8,120 | 17.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $12,977 | $2,375 | 18.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $9,501 | $1,750 | 18.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 41 | 161 | $64,239 | $14,188 | 22.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 60 | $37,122 | $7,682 | 20.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 36 | 58 | $35,984 | $7,447 | 20.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $12,939 | $2,784 | 21.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $8,261 | $1,821 | 22.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 23 | 23 | $6,463 | $1,408 | 21.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 15 | $5,025 | $1,302 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 14 | $4,626 | $971.08 | 21.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 42 | 59 | $20,881 | $5,152 | 24.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 25 | 25 | $13,019 | $3,340 | 25.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 45 | 55 | $11,785 | $2,727 | 23.1% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Facility | 2020 | 13 | 15 | $840.00 | $130.20 | 15.5% |
About Antonio Giordano, M.D., PH.D
Antonio Giordano, M.D., PH.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2013. The National Provider Identifier (NPI) number assigned to this provider is 1578902243.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Antonio Giordano, M.D., PH.D has received a total of $25,732 in payments from pharmaceutical and medical device companies, with $18,562 received in 2024. These payments were reported across 33 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($9,655).
As a Medicare-enrolled provider, Giordano has provided services to 569 Medicare beneficiaries, totaling 983 services with total Medicare billing of $100,827. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Boston, MA
- Active Since 06/17/2013
- Last Updated 03/19/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1578902243
Products in Payments
- IBRANCE (Drug) $4,305
- ELREXFIO (Drug) $1,270
- ENHERTU (Biological) $210.71
- GAMMA (Device) $120.25
- Orserdu (Drug) $97.01
- Trodelvy (Drug) $96.05
- KISQALI (Drug) $12.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795